Do you know your mutations? Genetics crossword

  • MPNRF | October 4, 2024

    Do you know about mutations?

    Instructions:  

    New genes and proteins are being discovered every year in the landscape of MPN research. Put your genetic know-how to the ultimate test with this advanced-level MPN crossword puzzle. Answers may include gene acronyms, mutations, and numbers, but no hyphens. You can find these answers below. 

    Answers:

    Screenshot 4 10 2024 143120 crosswordlabs.com

    Sources:  

    Guglielmelli, P., & Calabresi, L. (2021). The MPL mutation. In International Review of Cell and Molecular Biology (Vol. 365). 

    Hoffman, R., et al., (2007). Philadelphia Chromosome-Negative Myeloproliferative Disorders: Biology and Treatment. Biology of Blood and Marrow Transplantation, 13(64-72). 

    Kiladjian, J.J., et al., (2016). Interferon-alpha for the therapy of myeloproliferative neoplasms: Targeting the malignant clone. Leukemia, 30(4), 776–781. 

    Lasho, T. L., Finke, C. M., Hanson, C. A., Jimma, T., Knudson, R. A., Ketterling, R. P., Pardanani, A., & Tefferi, A. (2012). SF3B1 mutations in primary myelofibrosis: Clinical, histopathology and genetic correlates among 155 patients. Leukemia, 26(5), 1135–1137. https://doi.org/10.1038/leu.2011.320 

    Masubuchi, N., et al., (2020). Mutant calreticulin interacts with MPL in the secretion pathway for activation on the cell surface. Leukemia, 34(2), 499–509. 

    Nangalia, J., et al., (2015). DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype. Haematologica, 100(11), 438-442. 

    Tefferi, A., et al., (2014). CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: Clinical, cytogenetic and molecular comparisons. Leukemia, 28(7), 1472–1477. 

    Tefferi, A., et al., (2018). Revised cytogenetic risk stratification in primary myelofibrosis: Analysis based on 1002 informative patients. Leukemia, 32(5).  

    Vannucchi, A. M., et al., (2011). JAK2 allele burden in the myeloproliferative neoplasms: Effects on phenotype, prognosis and change with treatment. Therapeutic Advances in Hematology, 2(1), 21-32.